



**PB 64 of 2025**

## **National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025**

---

I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.

Dated 27 May 2025

Rebecca Richardson  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health, Disability and Ageing

---



---

## Contents

1 Name .....	1
2 Commencement.....	1
3 Authority .....	1
4 Schedules.....	1
<b>Schedule 1—Amendments commencing 1 June 2025</b>	<b>2</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
<b>Schedule 2—Amendments commencing 1 November 2025</b>	<b>10</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	10



---

## 1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025*.
- (2) This instrument may also be cited as PB 64 of 2025.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 June 2025.	1 June 2025
2. Schedule 1	1 June 2025.	1 June 2025
3. Schedule 2	1 November 2025.	1 November 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1—Amendments commencing 1 June 2025

### *National Health (Minimum Stockholding) Determination 2023*

#### 1 Schedule 1 (table)

After:				
Aripiprazole	Tablet 30 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand
insert:				
Arsenic	Injection concentrate containing arsenic trioxide 10 mg in 10 mL	Injection	Arsenic Trioxide-AFT	between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand

#### 2 Schedule 1 (table)

Omit:				
Azacitidine	Powder for injection 100 mg	Injection	Azacitidine-Teva	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand

#### 3 Schedule 1 (table)

After:				
Benzathine benzylpenicillin	Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
insert:				
Bisoprolol	Tablet containing bisoprolol fumarate 10 mg	Oral	NOUMED BISOPROLOL	between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	Oral	NOUMED BISOPROLOL	between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 5 mg	Oral	NOUMED BISOPROLOL	between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand

---

#### 4 Schedule 1 (table)

Omit:

Ciclosporin	Capsule 100 mg	Oral	Cyclosporin Sandoz	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand
-------------	----------------	------	--------------------	---

#### 5 Schedule 1 (table)

Omit:

Ciclosporin	Capsule 25 mg	Oral	Cyclosporin Sandoz	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand
-------------	---------------	------	--------------------	---

#### 6 Schedule 1 (table)

Omit:

Ciclosporin	Capsule 50 mg	Oral	Cyclosporin Sandoz	between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand
-------------	---------------	------	--------------------	---

#### 7 Schedule 1 (table)

After:

Dosulepin	Capsule containing dosulepin hydrochloride 25 mg	Oral	Dosulepin Viartis	6 months stock by reference to usual demand
Doxorubicin	Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial	Injection/Intravesical	Adriamycin	between 1 June 2025 and 30 June 2025—0 months stock by reference to usual demand

#### 8 Schedule 1 (table)

Omit:

Fentanyl	Transdermal patch 10.20 mg	Transdermal	Denpax	2.5 months stock by reference to usual demand
----------	----------------------------	-------------	--------	---

---

**9 Schedule 1 (table)**

Felodipine	After:	Tablet 2.5 mg (extended release)	Oral	Plendil ER	2.5 months stock by reference to usual demand
	insert:				
Fentanyl	insert:	Transdermal patch 1.28 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
Fentanyl		Transdermal patch 10.20 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
Fentanyl		Transdermal patch 12.6 mg	Transdermal	Durogesic 75	between 1 June 2025 and 31 July 2025— 0 months stock by reference to usual demand

**10 Schedule 1 (table)**

Fentanyl	After:	Transdermal patch 12.6 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
	insert:				
Fentanyl	insert:	Transdermal patch 16.8 mg	Transdermal	Durogesic 100	between 1 June 2025 and 31 July 2025— 0 months stock by reference to usual demand

**11 Schedule 1 (table)**

Fentanyl	After:	Transdermal patch 2.1 mg	Transdermal	APO-Fentanyl	3.5 months stock by reference to usual demand
	insert:				
Fentanyl	insert:	Transdermal patch 2.1 mg	Transdermal	Durogesic 12	between 1 June 2025 and 31 July 2025— 0 months stock by reference to usual demand
Fentanyl		Transdermal patch 2.55 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand



---

**12 Schedule 1 (table)**

Omit:

Fentanyl	Transdermal patch 5.10 mg	Transdermal	Denpax	2.5 months stock by reference to usual demand
----------	------------------------------	-------------	--------	---

**13 Schedule 1 (table)**

After:

Fentanyl	Transdermal patch 4.2 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
----------	-----------------------------	-------------	--------------	---

insert:

Fentanyl	Transdermal patch 4.2 mg	Transdermal	Durogesic 25	between 1 June 2025 and 31 July 2025— 0 months stock by reference to usual demand
----------	-----------------------------	-------------	--------------	---

Fentanyl	Transdermal patch 5.10 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
----------	------------------------------	-------------	--------	--

Fentanyl	Transdermal patch 7.65 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
----------	------------------------------	-------------	--------	--

**14 Schedule 1 (table)**

After:

Fentanyl	Transdermal patch 8.4 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
----------	-----------------------------	-------------	--------------	---

insert:

Fentanyl	Transdermal patch 8.4 mg	Transdermal	Durogesic 50	between 1 June 2025 and 31 July 2025— 0 months stock by reference to usual demand
----------	-----------------------------	-------------	--------------	---

**15 Schedule 1 (table)**

After:

Fluconazole	Powder for oral suspension 50 mg in 5 mL, 35 mL	Oral	Diflucan	4 months stock by reference to usual PBS demand
-------------	---	------	----------	---

insert:

Fluoxetine	Capsule 20 mg (as hydrochloride)	Oral	Fluoxetine APOTEX	between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand
------------	-------------------------------------	------	-------------------	--

---

**16 Schedule 1 (table)**

Omit:

Furosemide	Tablet 40 mg	Oral	NOUMED FUROSEMIDE	between 1 April 2025 and 31 May 2025— 0 months stock by reference to usual demand
------------	--------------	------	----------------------	---

**17 Schedule 1 (table)**

Omit:

Iron polymaltose complex	Injection 100 mg (iron) in 2 mL	Injection	Ferrosig	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
-----------------------------	------------------------------------	-----------	----------	---

**18 Schedule 1 (table)**

After:

Isoleucine with carbohydrate	Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)	Oral	Isoleucine 50	0 months stock by reference to usual PBS demand
insert:				
Lamivudine	Tablet 150 mg	Oral	Lamivudine Viatris	after 30 September 2025—4 months stock by reference to usual demand of both Lamivudine Viatris and Lamivudine Alphapharm added together

**19 Schedule 1 (table)**

Omit:

Methylprednisolone	Powder for injection 1 g (as sodium succinate)	Injection	Solu-Medrol	between 1 May 2025 and 31 May 2025— 0 months stock by reference to usual demand
--------------------	--	-----------	-------------	---

**20 Schedule 1 (table)**

Omit:

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	Mycophenolate APOTEX	4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX- MYCOPHENOLAT E added together
-------------------	--	------	-------------------------	---

---

## 21 Schedule 1 (table)

After:				
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral	Zofran syrup 50 mL	4 months stock by reference to usual PBS demand
insert:				
Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	Ondansetron ODT Viatris	after 30 September 2025—6 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together

## 22 Schedule 1 (table)

After:				
Promethazine	Injection containing promethazine hydrochloride 50 mg in 2 mL	Injection	DBL Promethazine Hydrochloride	6 months stock by reference to usual PBS demand
insert:				
Propylene glycol	Eye drops 60 micrograms per mL, 10 mL	Application to the Eye	Systane Balance	4 months stock by reference to usual PBS demand

## 23 Schedule 1 (table)

After:				
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	Oral	Parbezol	4 months stock by reference to usual demand
insert:				
Rabeprazole	Tablet containing rabeprazole sodium 10 mg (enteric coated)	Oral	Pariet	between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand
Rabeprazole	Tablet containing rabeprazole sodium 20 mg (enteric coated)	Oral	Pariet	between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand

## 24 Schedule 1 (table)

Omit:				
Ramipril	Capsule 10 mg	Oral	Ramipril Winthrop	between 1 April 2025 and 31 May 2025—0 months stock by reference to usual demand

## 25 Schedule 1 (table)

After:				
Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir ARX	4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together
insert:				
Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Viread	between 1 June 2025 and 30 September 2025—2 months stock by reference to usual demand

## 26 Schedule 1 (table)

After:				
Tenofovir	Tablet containing tenofovir disoproxil maleate 300 mg	Oral	Tenofovir Disoproxil Viatris	after 31 January 2025—4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together
insert:				
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	CIPLA TENOFOVIR + EMTRICITABINE 300/200	between 1 June 2025 and 30 September 2025—4 months stock by reference to usual demand

## 27 Schedule 1 (table)

Omit:				
Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	Tenofovir/Emtricitabine 300/200 APOTEX	3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together

## 28 Schedule 1 (table)

Omit:				
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	APO-Sodium Valproate	between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing	Oral	Epilim EC	between 1 December 2024 and 31 May

	sodium valproate 200 mg			2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Sodium Valproate Sandoz	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Valprease 200	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Valpro EC 200	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 200 mg	Oral	Valproate Winthrop EC 200	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	APO-Sodium Valproate	between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Epilim EC	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Sodium Valproate Sandoz	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Valprease 500	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Valpro EC 500	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
Valproic acid	Tablet (enteric coated) containing sodium valproate 500 mg	Oral	Valproate Winthrop EC 500	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand

---

## Schedule 2—Amendments commencing 1 November 2025

### *National Health (Minimum Stockholding) Determination 2023*

#### 1 Schedule 1 (table)

Tenofovir	After:	Tablet containing tenofovir disoproxil maleate 300 mg	Oral	Tenofovir Disoproxil Viatis	after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatis and Tenofovir Disoproxil Mylan added together
	insert:				
Tenofovir with emtricitabine		Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg	Oral	TENOFOVIR/EMT RICITABINE 300/200 APX	6 months stock by reference to usual demand